selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T-cell mediated autoimmune diseases, announced positive results from the first-in-human Phase 1b trial of its lead compound, si-544, in atopic dermatitis patients.
April 29, 2024
· 5 min read
